ING Groep NV Buys New Position in Masimo Corporation $MASI

ING Groep NV purchased a new position in shares of Masimo Corporation (NASDAQ:MASI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,800 shares of the medical equipment provider’s stock, valued at approximately $3,069,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MASI. Versor Investments LP purchased a new position in shares of Masimo during the third quarter worth approximately $332,000. Navellier & Associates Inc. acquired a new stake in Masimo during the 3rd quarter worth $931,000. Oppenheimer Asset Management Inc. boosted its stake in Masimo by 61.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,797 shares of the medical equipment provider’s stock worth $413,000 after purchasing an additional 1,064 shares during the period. Smartleaf Asset Management LLC grew its position in Masimo by 80.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 136 shares during the last quarter. Finally, State of Michigan Retirement System increased its stake in Masimo by 1.9% in the third quarter. State of Michigan Retirement System now owns 10,996 shares of the medical equipment provider’s stock valued at $1,622,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Stock Down 2.1%

MASI opened at $130.15 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92. Masimo Corporation has a 12 month low of $125.94 and a 12 month high of $194.88. The stock has a market capitalization of $6.99 billion, a P/E ratio of -12.35, a P/E/G ratio of 1.35 and a beta of 1.26. The business has a 50 day simple moving average of $136.49 and a 200-day simple moving average of $142.83.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MASI shares. Bank of America started coverage on shares of Masimo in a research note on Monday, November 17th. They set a “neutral” rating and a $162.00 target price for the company. BTIG Research upped their price objective on Masimo from $198.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Monday, December 1st. Finally, Zacks Research cut Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Masimo currently has an average rating of “Hold” and a consensus price target of $189.40.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.